4/A: Director McGrath Acquires 300,000 CTOR Restricted Shares

Citius Oncology Director Dennis M. McGrath was granted 300,000 restricted common stock awards vesting in three years.

Summary

• Dennis M. McGrath, a Director of Citius Oncology, Inc. (CTOR), acquired 300,000 shares of common stock.
• These shares were granted as restricted stock awards on September 19, 2025, with a transaction price of $0.
• The shares will vest in full on the third anniversary of the grant date, which is September 19, 2028.
• Vesting is contingent upon Mr. McGrath's continuous service to Citius Oncology, Inc. or a related entity.
• Following this transaction, Mr. McGrath beneficially owns 300,000 shares directly.

Sentiment

Score: 7

Explanation: The grant of restricted stock to a director is generally a positive signal, indicating alignment of interests and a long-term commitment. The size of the grant (300,000 shares) is significant. However, it's a compensation event, not a direct investment by the director with personal capital, which slightly tempers the sentiment compared to an open market purchase.

Positives

• The grant of restricted stock awards aligns the director's interests with long-term shareholder value through a three-year vesting schedule.
• The acquisition of 300,000 shares by a director demonstrates confidence in the company's future prospects.

Negatives

• The shares are restricted and do not provide immediate liquidity to the director.
• The $0 transaction price indicates a grant rather than an open market purchase, which might be viewed differently by some investors.

Risks

• The vesting of the restricted stock is subject to the director's continuous service, meaning the shares could be forfeited if service is terminated before the vesting date.

Future Outlook

The restricted stock awards are designed to incentivize long-term commitment and performance from the director, with full vesting contingent on continuous service until September 19, 2028.

Industry Context

Grants of restricted stock to directors are a common practice in the biotechnology and pharmaceutical industries, aiming to align executive and director incentives with long-term company performance and shareholder interests, particularly given the extended development cycles inherent in oncology.

Comparison to Industry Standards

• The grant of restricted stock awards to directors is a standard compensation practice across many industries, including biotechnology, to foster long-term alignment.
• A three-year vesting schedule is typical for such equity grants, comparable to practices seen at companies like Amgen or Gilead Sciences for their non-employee directors.
• The $0 price for restricted stock grants is standard, as it represents an award rather than a purchase.

Stakeholder Impact

• Shareholders: Potential positive impact due to increased alignment of director's interests with long-term shareholder value.

Next Steps

• Mr. McGrath must maintain continuous service to Citius Oncology, Inc. or a related entity until September 19, 2028, for the restricted stock to vest.

Key Dates

Recommendation

This Form 4 reports a routine restricted stock grant to a director as part of their compensation package. While it indicates alignment of interests, it does not provide new fundamental information about the company's operational performance, financial health, or strategic direction that would warrant a change in investment recommendation. It's a standard insider transaction that doesn't significantly alter the investment thesis.

Keywords

Citius Oncology, CTOR, Form 4, Insider Trading, Restricted Stock, Director Compensation, Equity Grant, Beneficial Ownership